Results 191 to 200 of about 12,515 (211)
Some of the next articles are maybe not open access.
Treatment of polycythemia vera with imatinib mesylate
Leukemia Research, 2012We treated 37 patients with polycythemia vera with imatinib mesylate (IM). The overall response rate was 49%. Thirty percent had a complete response, and 19%, a partial response. Thirty-one patients were treated for >120 days. Frequent side effects included nausea, diarrhea, edema, and skin rash.
Eric J. Feldman +6 more
openaire +3 more sources
Imatinib mesylate in polycythemia vera
Blood, 2004In the September 15, 2003, issue of Blood, [1][1] Oehler et al describe imatinib mesylate inhibition of the autonomous in vitro proliferation of peripheral blood– and bone marrow–derived polycythemia vera (PV) erythroid burst-forming units (BFU-Es).
Richard T. Silver, Jerry L. Spivak
openaire +2 more sources
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis
American Journal of Hematology, 2003AbstractImatinib mesylate targets the adenosine triphosphate (ATP)‐binding sites of the protein tyrosine kinase domains associated with Bcr‐abl, the platelet‐derived growth factor (PDGF) and c‐kit. In idiopathic myelofibrosis (IMF) PDGF is considered to be one of the growth factors responsible for the development of bone marrow fibrosis.
B A Jensen +7 more
openaire +3 more sources
Imatinib Mesylate in Chronic Myeloid Leukemia
Current Stem Cell Research & Therapy, 2007Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology. Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation.
Angelo Michele Carella, Enrica Lerma
openaire +2 more sources
Imatinib mesylate in children and adolescents with cancer
Pediatric Blood & Cancer, 2010AbstractImatinib is an inhibitor of theBCR–ABLfusion gene product that characterizes chronic myeloid leukemia (CML), and of the related tyrosine kinases c‐KIT and platelet‐derived growth factor (PDGF) receptor. The drug is now included as front‐line therapy for CML and Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and ...
openaire +3 more sources
Antitumor activity of imatinib mesylate in neuroblastoma xenografts
Cancer Letters, 2005Imatinib mesylate has antitumor activity in vitro and in vivo against neuroblastoma cell lines and xenografts characterized by a different expression of receptor tyrosine kinases. In this article, we report that imatinib tumor concentration can be independent of the administered dose and does not correlate with the antitumor effect. In xenografts, high-
Josef Brueggen +8 more
openaire +4 more sources
2015
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence.
openaire +1 more source
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence.
openaire +1 more source
Imatinib Mesylate for Cerebral Langerhans'-Cell Histiocytosis
New England Journal of Medicine, 2004To the Editor: Langerhans'-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans' cells, eosinophils, neutrophils, macrophages, and lymphocytes.
Montella L +2 more
openaire +3 more sources
Imatinib mesylate in the treatment of chronic myeloid leukaemia [PDF]
Expert Opinion on Pharmacotherapy, 2003 Imatinib mesylate (Gleevec, Glivec), formerly STI571; Novartis Pharmaceuticals) is an inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid leukaemia (CML). The remarkable results of imatinib mesylate in clinical trials have rapidly and profoundly changed the management of patients with CML.
openaire +2 more sources
Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)
Pediatric Blood & Cancer, 2010AbstractDermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet‐derived growth factor β (PDGFβ) with the collagen type 1α1 (COL1α1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is ...
Saskia L. Gooskens +6 more
openaire +3 more sources